Nanoparticle albumin-bound-paclitaxel: A limited improvement under the current therapeutic paradigm of pancreatic cancer

Expert Opinion on Pharmacotherapy

Volumn 16, Issue 7, 2015, Pages 943-947

  Hoffman, Robert M ^a,b   Bouvet, Michael ^b  

^a ANTICANCER INC   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

Cell cycle decoy; Cell cycle specific drugs; Efficacy; Nanoparticle albumin bound; Paclitaxel; Pancreatic cancer; Salmonella typhimurium A1 R; Survival; Tumor targeting bacteria

Indexed keywords

CISPLATIN; GEMCITABINE; NECUPARANIB; PACLITAXEL; 130-NM ALBUMIN-BOUND PACLITAXEL; ALBUMINOID; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; NANOPARTICLE;

CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; CANCER SURVIVAL; CELL CYCLE PHASE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; G2 PHASE CELL CYCLE CHECKPOINT; HELA CELL LINE; HUMAN; HYDROPHOBICITY; MONOTHERAPY; NANOTECHNOLOGY; NEUROPATHY; NEUTROPENIA; NONHUMAN; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PATIENT SELECTION; PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; S PHASE CELL CYCLE CHECKPOINT; ANALOGS AND DERIVATIVES; ANIMAL; PANCREATIC NEOPLASMS; PATHOLOGY;

ALBUMINS; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEOXYCYTIDINE; HUMANS; NANOPARTICLES; PACLITAXEL; PANCREATIC NEOPLASMS;

EID: 84928534021     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2015.1016912     Document Type: Review

References (16)

1. Mentzer Jr. WC. Differentiation of iron deficiency from thalassaemia trait. Lancet. 1973;1(7808):882.
2. England JM, Fraser PM. Differentiation of iron deficiency from thalassaemia trait by routine blood count. Lancet. 1973; 1(7801):449-452.
3. Green R, King R. A new red cell discriminant incorporating volume dispersion for differentiating iron deficiency from thalassemia minor. Blood Cells. 1989;15(3):481-491.
4. Shine I, Lal S. A strategy to detect b thalassaemia minor. Lancet. 1977;1(8013):692-694.
5. Srivastava PC, Bevington JM. Iron deficiency and-or thalassaemia trait. Lancet. 1973;1(7807):832.
6. Steiner J, Marti HR, Dean D. Decreased Hemoglobin A2 concentration in iron deficiency anemia. Acta Haematol. 1971; 45(2):77-81.
7. Passarello C, Giambona A, Cannata M, et al. Iron deficiency does not compromise the diagnosis of high Hb A2 b thalassemia trait. Haematologica. 2012;97(3):472-473.
8. Galanello R, Ruggeri R, Addis M, et al. Hemoglobin A2 in iron deficient b-Thalassemia heterozygotes. Hemoglobin. 1981; 5(6):613-618.
9. Harthoorn-Lasthuizen EJ, Lindemans J, Langenhuijsen MM. Influence of iron deficiency anaemia on Haemoglobin A2 levels: Possible consequences for b-Thalassaemia screening. Scand J Clin Lab Invest. 1999;59(1):65-70.
10. Madan N, Sikka M, Sharma S, Rusia U. Phenotypic expression of Hemoglobin A2 in b-Thalassemia trait with iron deficiency. Ann Hematol. 1998;77(3):93-96.
11. Abolghasemi H, Amid A, Zeinali S, et al. Thalassemia in Iran: Epidemiology, prevention, and management. J Pediatr Hematol Oncol. 2007;29(4):233-238.
12. Balarajan Y, Ramakrishnan U, Ozaltin E, et al. Anaemia in low-income and middle-income countries. Lancet. 2011; 378(9809):2123-3215.
13. Giordano PC. Strategies for basic laboratory diagnostics of the hemoglobinopathies in multi-ethnic societies: Interpretation of results and pitfalls. Int J Lab Hematol. 2013;35(5):465-479.
14. Steinberg MH, Nagel RL. Hemoglobins of embryo, fetus, and adult. In: Steinberg MH, Forget BG, Higgs DR, Weatherall DJ, Eds. Disorders of Hemoglobin Genetics, Pathophysiology, and Clinical Management, 2nd ed. Cambridge, UK: Cambridge University Press. 2009:119-135.
15. Ben-Bassat I, Mozel M, Ramot B. Globin synthesis in irondeficiency anemia. Blood. 1974;44(4):551-555.
16. Steinberg MH, Adams JG 3rd. Hemoglobin A2: Origin, evolution, and aftermath. Blood. 1991;78(9):2165-2177.